Analyst Price Target is $17.40
▲ +97.06% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Nuvation Bio in the last 3 months. The average price target is $17.40, with a high forecast of $20.00 and a low forecast of $15.00. The average price target represents a 97.06% upside from the last price of $8.83.
Current Consensus is
The current consensus among 6 polled investment analysts is to buy stock in Nuvation Bio.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting CDK2, CDK4, and CDK6. It is also developing NUV-868, a selective inhibitor of the BET family of epigenetic transcriptional regulators; NUV-569, a differentiated selective inhibitor of the Wee1 kinase; NUV-1182, an adenosine receptor inhibitor; and DDC platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to androgen receptor-expressing cancer cells , as well as PARP inhibitor to ER-expressing cancer cells. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was incorporated in 2018 and is headquartered in New York, New York.